All In Biotech

Drug Trial Radar · NCT02577406

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 319 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

319

Actual

Start

Dec 30, 2015

Primary completion

Mar 17, 2020

Study completion Mar 25, 2024

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.

Conditions

  • Leukemia, Myeloid
  • Isocitrate Dehydrogenase

Interventions

  • AG-221Drug

    Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days

  • BSCOther

    Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support

  • AzacitidineDrug

    continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC

  • Low-dose cytarabine (LDAC)Drug

    continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC

  • Intermediate-dose cytarabine (IDAC)Drug

    28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization to death due to any cause (up to approximately 49 months)

Locations

93 sites in 18 countries. Site status is shown where the registry gives one.

  • Local Institution - 121

    Miami, Florida

  • University of Florida Health Cancer Center at Orlando Health

    Orlando, Florida

  • Local Institution - 111

    Chicago, Illinois

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Local Institution - 128

    New York, New York

  • Strong Health System

    Rochester, New York

  • Montefiore Medical Center Albert Einstein Cancer Center

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Local Institution - 104

    Greenville, South Carolina

  • Baylor Sammons Cancer Center

    Dallas, Texas

  • Local Institution - 906

    East Melbourne, Australia

  • Local Institution - 905

    Melbourne, Australia

  • Local Institution - 901

    Concord, New South Wales, Australia

  • Local Institution - 904

    Adelaide, South Australia, Australia

  • Local Institution - 803

    Linz, Austria

  • Local Institution - 811

    Yvoir, Belgium

  • Local Institution - 251

    Jaú, Brazil

  • Local Institution - 253

    Rio de Janeiro, Brazil

  • Local Institution - 254

    São Paulo, Brazil

  • Local Institution - 250

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution - 252

    Porto Alegre, RS, Rio Grande do Sul, Brazil

  • Local Institution - 202

    Edmonton, Alberta, Canada

  • Local Institution - 203

    Winnipeg, Manitoba, Canada

  • Local Institution - 201

    Toronto, Ontario, Canada

  • Local Institution - 204

    Montreal, Quebec, Canada

  • Local Institution - 885

    Beijing, China

  • Local Institution - 884

    Beijing, China

  • Local Institution - 892

    Beijing, China

  • Local Institution - 888

    Chengdu, Sichuan, China

  • Local Institution - 882

    Fuzhou, China

  • Local Institution - 881

    Guangzhou, Guangdong, China

  • Local Institution - 883

    Hangzhou, China

  • Local Institution - 887

    Shanghai, China

  • Local Institution - 891

    Shanghai, China

  • Local Institution - 889

    Zhengzhou, China

  • Local Institution - 822

    Prague, Czechia

  • Local Institution - 834

    Aalborg, Denmark

  • Local Institution - 833

    Arhus C, Denmark

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.